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Abstract Migraine and epilepsy are both chronic disorders
characterised by recurrent neurological attacks, with a par-
tial clinical and therapeutic overlap and frequently occur-
ring together. Although still incompletely clarified, the
possible existence of a link between migraine and epilep-
sy has long been debated. In this paper the epidemiologic
evidence of migraine and epilepsy comorbidity, the possi-
ble occurrence of both disturbances in close temporal asso-
ciation, possible shared physiopathologic mechanisms and
the rationale for antiepileptic drug use in migraine prophy-
laxis will be discussed.
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Background
Migraine and epilepsy are among the commonest neurolog-
ical diseases observed in outpatient neurological settings.
Although still incompletely clarified, the possible existence
of a link between migraine and epilepsy has long been
debated [1]. Both disorders are characterised by recurrent
neurological attacks with a partial clinical and therapeutic
overlap. A number of symptoms, including post-event
lethargy, impaired or loss of consciousness, visual distur-
bances, visual and hormonal triggering factors, vertigo,
paraesthesias, hemiparesis and aphasia, can be commonly
observed in both conditions [2]. Moreover there is evidence
of an epidemiological association between these two condi-
tions. Besides similarities, a number of substantial differ-
ences between migraine and epilepsy are to be highlighted.
The prevalence of idiopathic forms is much more frequent in
migraine than in epilepsy; the definite female prevalence
reported in migraine is not evident in epilepsy [3]. Migraine
prevalence is low during childhood, peaks in adult age,
above all in women, and decreases in old age; on the con-
trary, epilepsy incidence is highest in extremes of life [4]. In
both diseases, monogenic forms are infrequent, but a famil-
ial transmission has been found more frequently in migraine.
Finally, because the consequences of even occasional
seizures are more health-threatening than those of migraine,
the traditional goal of epilepsy treatment is the complete
control of seizures whereas migraine treatment may be tai-
lored to the reduction of disability within satisfactory limits.
Migraine/epilepsy comorbidity
The prevalence of epilepsy ranges between 0.5% and 1.0%
in men and women [4]; the overall prevalence of migraine is
about 12% (15%–17% in women and about 6% in men) [5];
the occurrence of both disorders in the same individual only
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by chance is therefore expected in about 1% of migraineurs
and 12% of epileptic subjects. Available literature data sug-
gest that migraine and epilepsy are linked by a definite
comorbidity, i.e., they can be observed in the same individ-
ual more frequently than expected on the basis of coinciden-
tal association. One of the first studies in this field indicates
that the prevalence of epilepsy in persons with migraine
ranges from 1% to 17% with a median of 5.9%, substantial-
ly higher than the population prevalence of epilepsy [6]. On
the other side, the reported frequency of migraine in epilep-
tic populations ranges from 8.4% to 23.0% [7]. Although
other studies confirm this association, indicating that the risk
of migraine is more than twice as high in persons with
epilepsy than in persons without epilepsy [8], at least two
recent clinical investigations suggest that headache is not
encountered more frequently in patients with epilepsy than
in the normal population [9, 10]. The discordance of findings
may be referred to variation in the definitions of migraine
used in the different studies and also, in several studies, to
the absence of controls. Another problem is that most of the
available studies are from secondary or tertiary care settings:
as co-occurrence of diseases increases the probability for
medical help seeking, comorbidity may result in grossly
overestimation in outpatient clinical series and its evaluation
needs to be confirmed in community studies [11]. In a recent
study examining comorbidity in an unselected cohort of
patients the association between migraine and epilepsy was
not identified, suggesting that it could not be encountered in
an unselected population [10]. However, this cross-sectional
study used morbidity data recorded by general practitioners
that could have underdiagnosed migraine.
Remarkably, a strong association between migraine
with aura (MWA) and epilepsy has been recently suggest-
ed. In a recent study the distribution of seizures across the
various types of headache patients showed a strong preva-
lence in MWA (30.4%) with respect to the other forms of
primary headaches [12]. Another population-based case-
control study found that the risk for unprovoked seizures
was increased in children with MWA and not in patients
with migraine without aura [13]. Moreover, the frequency
of MWA was found to be significantly higher in patients
with comorbidity (41.0%) as compared to the patients with
migraine alone (25.8%) [14].
Although large population-based studies are needed to
confirm the overall association between migraine and
epilepsy, the existence of a definite comorbidity can hard-
ly be denied, at least in MWA patients.
Mechanisms of comorbidity
Mechanisms underlying the epidemiological association
between migraine and epilepsy remain uncertain. The
three main possibilities are: (1) migraine is a risk factor for
epilepsy (for example, by causing cerebral ischaemia and
injury); (2) epilepsy is a risk factor for migraine (possibly,
by trigeminovascular system activation); and (3) migraine
and epilepsy share a pathogenic factor, either acquired or
on a genetic basis, leading to a reciprocal risk factor effect.
According to the first hypothesis we would expect the inci-
dence of migraine to be elevated before, but not after, the
onset of epilepsy. The second hypothesis leads us to expect
an excess risk of migraine after, but not before, the onset
of epilepsy. The data from a pivotal association study [8]
showed that there is an excess risk of migraine both before
and after seizure onset, leading to the rejection of both uni-
directional casual models and supporting a bidirectional
comorbidity that reliably suggests the existence of shared
pathogenic mechanisms between the two conditions.
Ottman and Lipton tested the hypothesis that shared genet-
ic risk factors might account for comorbidity but the analy-
sis failed to confirm this hypothesis because migraine was
no more likely in individuals with familial epilepsy than in
those without familiality [15]. The authors proposed that
the increased cortical excitability that characterises both
the diseases might represent the common pathogenic step
that can explain the bidirectional comorbidity.
Clinical presentations of migraine/epilepsy comorbidity
In most patients suffering from both migraine and epilep-
sy the attacks present without a strict chronological corre-
lation, thus reflecting a pure epidemiological comorbidity.
Nonetheless, migraine and epilepsy may occur in close
temporal relation and a headache attack may precede,
accompany or follow an epileptic attack.
Migraine and epilepsy occurring in close temporal relation
Chapter 7 of the International Classification of Headache
Disorders – II (ICHD-II) [16] validates “7.6.1 Hemicrania
epileptica” and “7.6.2 Post-ictal headache” as headaches
attributed to epileptic seizures and provides specific sets of
diagnostic criteria. A third possible simultaneous presenta-
tion of both disorders, limited to MWA patients, refers to the
occurrence of a seizure during a typical migrainous aura, an
infrequent condition also known as “migralepsy”; the ICHD-
II codes this form as “1.5.5 Migraine-triggered seizures” and
classify it among the migraine complications; diagnostic cri-
teria require that a seizure, regardless of which type, occurs
during or within 1 h after a typical migraine aura.
Although not present in the ICHD-II, cases of a pre-ictal
headache (PIHA) not related to a migrainous aura are
described. This condition has only rarely been reported
[17–19]. In a study on 100 consecutive patients with phar-
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macologically refractory partial epilepsy, 11 of them report-
ed PIHA: 7 had early PIHA (within 30 min before seizure
onset) and 4 had prodromic PIHA (24 h to 30 min before
seizure onset). PIHA was ipsilateral to the seizure focus in
all but one and had migrainous characteristics in four [20].
Hemicrania epileptica
Hemicrania epileptica (7.6.1) is a rather uncommon condi-
tion; according to ICDH-II criteria it can be diagnosed
when a migrainous headache lasting seconds to minutes
occurs during the ictal phase of a partial seizure, ipsilater-
ally to the epileptic discharge. Thus the diagnosis requires
an electroencephalographic demonstration of both the syn-
chronicity and the ipsilaterality of manifestations. In a
series, only 3 out of 135 (2.2%) epileptic patients had an
ictal headache; reported duration of pain ranged between
30 and 60 s [9].
Post-ictal headache (PIH)
Post-ictal headache (PIH) (7.6.2) is a consequence of a
seizure discharge that can be frequently observed in occip-
ital lobe seizures but can complicate either partial or gen-
eralised seizures. It may present with tension-type features
but can be indistinguishable from a true migraine, espe-
cially in migrainous patients. ICDH-II criteria for PIH
require the onset of pain within 3 h after a seizure and its
resolution within 72 h. As many as 50% of epileptic
patients complain of a post-ictal headache [17, 18, 21, 22]
although prevalence may vary in function of epilepsy type
with a higher prevalence in localisation-related occipital
lobe epilepsy (OLE). In a study [23] PIH occurred in 41%
of temporal lobe epilepsy (TLE) patients, 40% of frontal
lobe epilepsy (FLE) patients and 59% of OLE patients. In
a series of epileptic patients, migrainous features were
found in 26% of subjects reporting post-ictal headache
(10% of the total study population). Distribution according
to epilepsy type showed a significantly higher prevalence
of migraine-like PIH in OLE and TLE than in FLE.
Interestingly, a history of migraine does not predict the
occurrence of PIH although the incidence of interictal
migraine is significantly higher in patients with migraine-
like PIH [24] and responsiveness to sumatriptan has been
anecdotally reported in PIH [25]. These observations sug-
gest that PIH is a part of epileptic manifestations as its
incidence is not affected by a previous history of migraine.
Nonetheless, susceptibility to migraine may be predictive
of a migraine-like PIH.
Migraine-triggered seizures (migralepsy) (1.5.5)
In a minority of MWA patients an epileptic attack may be
precipitated by an otherwise typical visual aura. Although
included in the ICDH-II classification, the nosography of
migralepsy is still a matter of debate. Although cortical
changes induced by the aura phase of migraine may account
for the triggering of an epileptic attack in predisposed sub-
jects, migralepsy is observed more rarely than expected
considering the high comorbidity rates of migraine and
epilepsy. In a series of 412 epileptic patients, migraine-trig-
gered seizures were found in only 1.7% of cases [26], while
other series report up to 16% [7]. In addition, the elemen-
tary visual hallucinations that precede pain onset in idio-
pathic or symptomatic occipital seizures may represent the
only ictal symptom in such patients, thus mimicking a typ-
ical aura migraine. Actually, idiopathic OLE with post-ictal
pain is frequently misdiagnosed as MWA, or as migralepsy
when a progression to extraoccipital manifestations or con-
vulsions do occur [27]. Many features of occipital ictal hal-
lucinations help in its diagnostic differentiation from
migraine visual aura. These include [28]:
– an usual duration of less then 30 s that rarely can reach
1 min and only exceptionally can last more than 3 min
as opposed to the 5–60 min of a typical aura;
– the perception of multiple small circular spots, almost
always bright coloured, appearing in a temporal hemi-
field and moving horizontally towards the opposite side
while increasing in size, a pattern very different from
the “fortification spectrum” or the “scintillating sco-
toma”, slowly spreading from point of fixation to one
hemifield and leaving variable degrees of blindness in
its wake that characterise a visual aura;
– the daily frequency often reported for attacks in idio-
pathic occipital epilepsy as opposed to a few per year
to a few per month frequency commonly observed in
migraine aura patients.
Symptomatic co-occurrence of migraine and epilepsy
Finally, the bleeding of an intracranial vascular malforma-
tion, either spontaneous or post-traumatic, severe head
traumas, and the rare “mitochondrial myopathy with
encephalopathy, lactic acidosis and stroke syndrome”
(MELAS) may present with simultaneous occurrence of
migraine and epilepsy.
Independent occurrence of migraine and epilepsy
Despite the reciprocal influences, migraine and epilepsy
occur independently in most comorbid cases. Studies on the
clinical characteristics of patients with migraine and epilep-
sy fail to reveal a specific epileptic profile in subjects with
migraine comorbidity. On the contrary, a severe pain, the
aggravation by routine physical activity, the presence of
photo and phonophobia, and the presence of aura were more
frequent in migrainous patients with epileptic comorbidity
than in those without [14]. These findings further support the
hypothesis that an altered excitability status of cerebral cor-
tex may be the link between migraine and epilepsy. As
migraine is frequently underdiagnosed and undertreated in
epileptic patients [19] and considering the risk of OLE mis-
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diagnosis, the presence of each disorder should raise the sus-
picion of the possible presence of the other.
Pathophysiologic relations between migraine and epilepsy
Similar mechanisms in these disorders are kindling/central
sensitisation and neuronal hyperexcitability.
Kindling vs. sensitisation
Kindling is the phenomenon by which repetitive induction
of epileptic fits makes the cortex more excitable to the
stimulus. The rat amygdala kindling is the best known
experimental model of epilepsy [29]. This process can be
involved in progressive worsening of epileptic syndromes
and may account for refractoriness to treatments observ-
able in up to 40% of patients [30].
On the other hand, painful sensitisation of trigeminal
and thalamic sensitive neurons has been suggested as the
mechanism of cutaneous allodynia [31]. This mechanism,
documented after chronic exposure to opiates [32], may
be involved in “medication overuse headache”, a
migraine-related condition associated with excessive use
of acute treatment compounds, characterised by the pro-
gression of attack frequency up to a daily chronic
headache and by a poor response to treatments [33].
Cortical hyperexcitability in migraine
If no doubt exists about the role of focal or generalised
hyperexcitability in epileptogenesis, the concept of corti-
cal hyperexcitability as a pivotal factor in migraine is more
recent. Welch et al. [34] proposed that an altered excitabil-
ity status of occipital cortex may be an important patho-
genic factor for migraine, probably lowering the threshold
for the development of cortical spreading depression
(CSD), the neurophysiologic event underlying MWA. In
recent years more lines of evidence supported the exis-
tence of such an altered excitability state, in both migraine
with and without aura [35, 36]. Hypothesised mechanisms
include impaired mitochondrial metabolism, derangement
of ion channels and reduced magnesium levels [37].
Hyperexcitability: the pathogenetic link between migraine
and epilepsy
If the bidirectional comorbidity between migraine and
epilepsy were sustained by a shared neuronal hyperex-
citability, thus a functional interference between CSD and
epileptic discharges should be observed at experimental
level. A study on human epileptic brain tissue found a
higher network excitability induced by elevated K+ extra-
cellular concentration, a condition knowing to occur as a
result of CSD [38]. Moreover, experimentally induced
CSD in human neocortical slices was able to induce sharp
potentials [39]. These findings strongly suggest that a rec-
iprocal facilitating interference represents the pathogenic
link between migraine and epilepsy and may account for
the epidemiological association of these diseases.
The rationale for antiepileptic drugs (AEDs) in migraine
Due to the above considerations, it is not surprising that
certain AEDs acting by modulating neuronal function are
effective in the prophylactic management of migraine,
confirming the pathogenetic link also from a clinical point
of view. At present the efficacy of topiramate and valproate
in migraine prophylaxis is confirmed by a number of ran-
domised controlled studies [40–43]; nonetheless emerging
evidence indicates that lamotrigine [44], gabapentin [45],
levetiracetam [46] and zonisamide [47] may be effective as
well. AEDs are effective in migraine therapy probably
because they act on brain excitability: topiramate reduces
CSD in rat brain [48]; in a magneto-encephalographic
study the neuronal excitability was reduced after a 30-day
sodium valproate treatment [36].
Conclusions
Epilepsy and migraine remain two substantially different
diseases, probably showing more differences than similar-
ities. A shared neuronal hyperexcitability may be the
pathophysiological link accounting for their bidirectional
comorbidity and for the efficacy showed by AEDs in
migraine. If the exposure to the side effects profile of
AEDs appears to be always justified in epileptic patients,
in migraine subjects the risk/benefit ratio of an AED pro-
phylaxis should be individually assessed.
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